John Öhd, Modus Therapeutics' CEO, commented:”2024 has been a transformational year for Modus Therapeutics, marked by groundbreaking clinical progress and a reinforced pipeline. With a clear vision and strong scientific foundations, we are poised to drive innovation in delivering innovative treatments for disorders of high need.”

The fourth quarter in figures

• The loss after tax amounted to TSEK 4 713 (4 069).
• The loss per share amounted to SEK 0,13 (0,18).
• The cash flow from current operations was negative in the amount of TSEK 3 619 (3 126).

The full year in figures

• The loss after tax amounted to TSEK 15 545 (17 897).
• The loss per share amounted to SEK 0,43 (1,01).
• The cash flow from current operations was negative in the amount of TSEK 14 681 (16 684).

Important events during the fourth quarter

• Modus Therapeutics receives a recruitment update from the collaborative Phase Ib study in severe malaria.
• Modus Therapeutics Receives Approval to Initiate a Phase IIa Clinical Trial for Chronic Kidney Disease (CKD).
• Modus Therapeutics secures access to bridge financing of 5 MSEK from Karolinska Development.
• New Article on Sevuparin Published in HemaSphere.
• Modus Therapeutics Initiates Phase II Study with Sevuparin for the Treatment of Chronic Kidney Disease with Anemia.
• Modus Therapeutics presents LPS Study Data at Pharmacology 2024.

Important events after the end of the period

• Modus Therapeutics receives a recruitment update from the collaborative Phase Ib study in severe malaria.

CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid on February 20 at 11:00. Link to Interview: https://www.youtube.com/watch?v=mZnLJkp0phc